Aptose to Report Fourth Quarter and Full Year 2021 Financial Results and Hold Conference Call on Tuesday, March 22, 2022

Rhea-AI Summary

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS) announced it will release financial results for the year and quarter ended December 31, 2021, on March 22, 2022, post-market close. The report will include a corporate update. A conference call is scheduled for the same day at 5:00 PM ET, accessible via dial-in and webcast. Key products in Aptose's pipeline include two oral kinase inhibitors aimed at treating hematologic malignancies, currently undergoing various clinical trials.

Positive

• Aptose is advancing two clinical-stage oral kinase inhibitors targeting hematologic malignancies.
• Ongoing international Phase 1/2 trial for HM43239 in relapsed/refractory AML.
• Luxeptinib is in trials for B cell malignancies and AML, expanding potential market reach.

Negative

• None.

SAN DIEGO and TORONTO, March 08, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the year and quarter ended December 31, 2021, on Tuesday, March 22, 2022 after the close of the market, and provide a corporate update.

Conference Call & Webcast:

Date:	Tuesday, March 22, 2022
Time:	5:00 PM ET
Dial In - Toll-Free:	1 844-882-7834
Dial In - International:	1 574-990-9707
Conference ID:	1644638
Webcast:	link

The live conference call can also be accessed through a link on the Investor Relations section of Aptose’s website here. An archived version of the webcast along with a transcript will be available on the company’s website for 30 days.

The press release, the financial statements and the management’s discussion and analysis for the year and quarter ended December 31, 2021 will be available on SEDAR at www.sedar.com and EDGAR at www.sec.gov/edgar.shtml.

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: HM43239, an oral, myeloid kinome inhibitor in an international Phase 1/2 trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib, an oral, dual lymphoid and myeloid kinome inhibitor in a Phase 1 a/b trial in patients with relapsed or refractory B cell malignancies who have failed or are intolerant to standard therapies, and in a separate Phase 1 a/b trial in patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS). For more information, please visit www.aptose.com.

For further information, please contact:

Aptose Biosciences Inc.	LifeSci Advisors, LLC
Susan Pietropaolo Investor Relations 201-923-2049 spietropaolo@aptose.com	Dan Ferry, Managing Director 617-535-7746 Daniel@LifeSciAdvisors.com

FAQ

When will Aptose Biosciences report its financial results for Q4 2021?

Aptose Biosciences will report its financial results for the year and quarter ended December 31, 2021, on March 22, 2022.

What will Aptose Biosciences discuss in its upcoming conference call on March 22, 2022?

The conference call will include the financial results and a corporate update.

What is the focus of Aptose Biosciences' clinical-stage pipeline?

Aptose focuses on developing precision medicines for hematologic malignancies with oral kinase inhibitors.

What are the names of Aptose's oral kinase inhibitors in development?

The oral kinase inhibitors in development are HM43239 and luxeptinib.